ライフサイエンスコーパス: heart transplantation

1 the short-term and long-term prognosis after heart transplantation.

2 re were 33 069 patients (25% women) awaiting heart transplantation.

3 om subjects undergoing LVAD placement and/or heart transplantation.

4 vanced heart failure who were ineligible for heart transplantation.

5 iated with allograft rejection in kidney and heart transplantation.

6 nvolved in allograft rejection in kidney and heart transplantation.

7 improved graft survival in primary pediatric heart transplantation.

8 val has been primarily due to utilization of heart transplantation.

9 Supraventricular tachycardia is common after heart transplantation.

10 ion and cardiac allograft vasculopathy after heart transplantation.

11 ion, ventricular assist device placement, or heart transplantation.

12 arison to non-ACHD patients while listed for heart transplantation.

13 enocyte immunization in vivo, and allogeneic heart transplantation.

14 al and cardiomyocyte recovery from IRI after heart transplantation.

15 ents with heart failure, LVAD, or orthotopic heart transplantation.

16 s, 375 patients (26.6%) experienced death or heart transplantation.

17 ndent predictor of long-term mortality after heart transplantation.

18 A total of 2384 patients underwent heart transplantation.

19 e Achilles' heel of long-term survival after heart transplantation.

20 e frailty phenotype in patients referred for heart transplantation.

21 ct the outcomes for ACHD patients listed for heart transplantation.

22 RHF persists as a complication of pediatric heart transplantation.

23 s of ischemia-reperfusion injury (IRI) after heart transplantation.

24 ion between ASP and long-term mortality post-heart transplantation.

25 decompensated patients to permanent LVAD or heart transplantation.

26 heart failure and the leading indication for heart transplantation.

27 d transplanted vasculature in children after heart transplantation.

28 ) correlated with all-cause death, LVAD, and heart transplantation.

29 primary endpoint was overall survival after heart transplantation.

30 cedures in patients before and after lung or heart transplantation.

31 the overall level of immunosuppression after heart transplantation.

32 primary end point was all-cause mortality or heart transplantation.

33 apy can be used to support children awaiting heart transplantation.

34 erfusion injury in a rat model of kidney and heart transplantation.

35 as), and 2 were on amiodarone as a bridge to heart transplantation.

36 ations are common in patients after lung and heart transplantation.

37 tor of allograft tolerance in a rat model of heart transplantation.

38 revalence among patients that have undergone heart transplantation.

39 B cell repertoire to immunosuppression after heart transplantation.

40 c antibodies seem to impact graft outcome in heart transplantation.

41 ction in an immunocompetent patient prior to heart transplantation.

42 recovery, mechanical circulatory support or heart transplantation.

43 CMR) and early onset of microvasculopathy in heart transplantation.

44 6 months, a proportion of 48% PPCMP received heart transplantation.

45 ension in 74 patients 13.5+/-6.7 years after heart transplantation.

46 to prevent or treat rejection in orthotopic heart transplantation.

47 HLA matching on graft survival in pediatric heart transplantation.

48 the major cause of late allograft loss after heart transplantation.

49 rt reducing the survival rates for pediatric heart transplantation.

50 t exercise test, 19 patients died or were re-heart transplantation.

51 orporeal membrane oxygenation at the time of heart transplantation.

52 n adversely affect outcomes before and after heart transplantation.

53 ontext of mechanical circulatory support and heart transplantation.

54 id rise in hepatitis C virus-infected (HCV+) heart transplantation.

55 weight for donor-recipient size matching for heart transplantation.

56 ial infarction and of allograft injury after heart transplantation.

57 and blocks neutrophil recruitment following heart transplantation.

58 ulation in advanced HF, and regression after heart transplantation.

59 transplant; 1,006 (57.6%) of these underwent heart transplantation.

60 ent cardiac deposition, ultimately requiring heart transplantation.

61 orporeal membrane oxygenation at the time of heart transplantation.

62 nd dilated cardiomyopathy, leading causes of heart transplantation.

63 tify all relevant preclinical studies in DCD heart transplantation.

64 erapy, use of ventricular assist devices and heart transplantation.

65 and I levels during the first 24 hours after heart transplantation.

66 ccurred in 5 patients: 3 underwent emergency heart transplantation, 1 had left ventricular assist dev

67 g transplantation, 13 liver, 6 kidney, and 2 heart transplantation; 11 probable or proven IPA, 11 pos

68 Patients with HF were more likely to undergo heart transplantation (15/142 versus 1/147; P<0.001) or

69 of CMV replication (hazard ratio [HR] after heart transplantation, 2.60; 95% confidence interval [CI

70 haring) for all adults listed for orthotopic heart transplantation (2000-2015) with a listed diagnosi

71 ardiographic normalization (30% and 27%) and heart transplantation (24% and 24%) were similar, the de

72 vanced heart failure who were ineligible for heart transplantation, a small, intrapericardial, centri

73 his study demonstrated a survival benefit of heart transplantation across all ranges of estimated don

74 COVID-19 poses a challenge for heart transplantation, affecting donor selection, immuno

75 half of women with end-stage PPCPM received heart transplantation after 3 years of mechanical suppor

76 children and young adults being referred for heart transplantation after failed congenital heart surg

77 e end point was time to death or listing for heart transplantation after the CMR study.

78 ssociated with an increased risk of death or heart transplantation (all Ps<0.001).

79 d, in some cases, exclude the candidate from heart transplantation altogether.

80 rrhythmias, syncope, cardiomyopathy, angina, heart transplantation and coronary bypass grafts, corona

81 or pump failure or refractory VAs, including heart transplantation and durable mechanical circulatory

82 Advanced heart failure therapies, including heart transplantation and durable mechanical circulatory

83 an aortic valves, obtained in the context of heart transplantation and from patients who underwent su

84 ssociated with increased all-cause mortality/heart transplantation and heart failure-related hospital

85 opies can be safely performed after lung and heart transplantation and in patients on the waiting lis

86 is common in patients with CHF referred for heart transplantation and is associated with adverse car

87 anced symptomatic heart failure referred for heart transplantation and is associated with increased m

88 r advanced heart disease therapies including heart transplantation and mechanical circulatory support

89 We will demonstrate sex differences in heart transplantation and waitlist survival.

90 on injury, immunological consequences during heart transplantations and also to study remodeling of t

91 den cardiac death or equivalent, 4% required heart transplantation, and 13% died.

92 was used to estimate freedom from ICD shock, heart transplantation, and death.

93 outcomes included ICD-related complications, heart transplantation, and death.

94 ilability of circulatory support, orthotopic heart transplantation, and disease-specific treatments,

95 large cohort of patients with heart failure, heart transplantation, and left ventricular assist devic

96 Incidence of all-cause death, heart transplantation, and LVAD was independently relate

97 ar drugs to prevent and treat complications, heart transplantation, and mechanical circulatory suppor

98 ection, cardiac allograft vasculopathy after heart transplantation, and potentially bronchiolitis obl

99 CAV limits long-term survival after heart transplantation, and screening for CAV is performe

100 sex differences in mortality while awaiting heart transplantation, and the reason remains unclear.

101 r rabbit antithymocyte globulin (rATG) after heart transplantation, and there is currently wide varia

102 Nine patients underwent heart transplantation, and transplant-free survival to d

103 educes biomarkers of myocardial injury after heart transplantation, and-also considering its document

104 , 3.6 [1.5-8.5]; >20 Gy 4.6 [1.1-19.6]); for heart transplantation, anthracycline and mean heart radi

105 In heart transplantation, antibody-mediated rejection (AMR)

106 Women who survive to heart transplantation appear to have lower risk features

107 s related to IRI in liver, kidney, lung, and heart transplantation are discussed.

108 Graft allocation rules for heart transplantation are necessary because of the short

109 greater proportion of patients referred for heart transplantation are older and have more complex co

110 agnosis of myocarditis listed for orthotopic heart transplantation are younger, sicker, and recover m

111 t was the cumulative incidence of death with heart transplantation as a competing risk.

112 nd underwent open-heart surgery exclusive of heart transplantation as their first operation, we analy

113 proportion of patients with AHF who received heart transplantation at 1 year was 29% compared with 22

114 atically evaluates IEps in the modern era of heart transplantation at Stanford University Medical Cen

115 from anthracyclines are often precluded from heart transplantation because of a history of cancer.

116 ed for all patients in England who underwent heart transplantation between 1995 and 2014.

117 onal registry CRISTAL for first single-organ heart transplantation between January 2010 and December

118 66) newly registered on the waiting list for heart transplantation between January 2010 and December

119 on class III/IV) referred for assessment for heart transplantation between November 2011 and April 20

120 trated to improve renal function early after heart transplantation, but long-term outcome of such a s

121 Heart transplantation can be performed using carefully s

122 Pediatric heart transplantation can have excellent outcomes with s

123 port, cardiac arrest prevention, and optimal heart transplantation candidacy to improve outcomes for

124 , adjusted HR = 1.14 [0.54-2.22], p = 0.71), heart transplantation, cardiac and noncardiac mortality,

125 FM have an increased mortality and need for heart transplantation compared with those with NFM.

126 s study sought to investigate the benefit of heart transplantation compared with waiting while accoun

127 hy might be improved if the risk of death or heart transplantation could be predicted by risk factors

128 lt patients with severe systemic RV failure, heart transplantation currently remains the only long-te

129 ng to the International Society for Lung and Heart Transplantation definition, combining arterial oxy

130 revious CRT pacing did not affect mortality, heart transplantation, device therapies or arrhythmia bu

131 gle-center analysis, 523 patients undergoing heart transplantation during 1996 to 2009 were stratifie

132 Of 45 941 adults listed for orthotopic heart transplantation during this period, we identified

133 s for ventricular tachyarrhythmias (n=33) or heart transplantation for advanced heart failure (n=18 [

134 fluid (CSF) from a patient who had undergone heart transplantation for dilated cardiomyopathy 11 mont

135 tory-based assessment of patients undergoing heart transplantation for early risk stratification, pat

136 illators (ICDs) for sudden death prevention, heart transplantation for end-stage failure, surgical my

137 7 nonobstructive patients (2.8%) did require heart transplantation for progression to end stage versu

138 ul when considering the immediate benefit of heart transplantation for status 2 candidates in stable

139 Long-term heart transplantation-free survival at 9 years was lower

140 patients referred or on the waiting list for heart transplantation from March 2013 underwent frailty

141 edures in patients before and after lung and heart transplantation from May 1999 to September 2012 wa

142 Monkeys undergoing allogeneic heart transplantation given alemtuzumab were monitored f

143 edical management and the graft failure post-heart transplantation groups had higher 30-day survival

144 Heterotopic abdominal rat heart transplantation has been extensively used to inves

145 ities and are older because the criteria for heart transplantation has few absolute contraindications

146 The use of induction therapy in pediatric heart transplantation has increased.

147 children with cardiomyopathy who underwent a heart transplantation has not declined over the past 10

148 Several clinical risk factors for death and heart transplantation have been identified in patients w

149 munity and alloimmunity in a model of murine heart transplantation have clinical relevance to the kno

150 composite of death/ventricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-

151 had a higher risk of nonarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96

152 Outcome was defined as cardiovascular death, heart transplantation, heart failure hospitalization, an

153 onstriction (TAC) prior to MU by heterotopic heart transplantation (hHTx/MU).

154 outcomes and generalized adoption of DCD in heart transplantation, however, requires further develop

155 Status 2 candidates showed a benefit from heart transplantation; however, survival benefit was del

156 erally been considered a contraindication to heart transplantation; however, the data supporting this

157 Changes in heart transplantation (HT) donor and recipient demograph

158 The first year after heart transplantation (HT) has the highest risk of morta

159 Long-term cardiac remodeling after heart transplantation (HT) in children has been insuffic

160 e implantable cardioverter-defibrillator and heart transplantation (HT) in patients with hypertrophic

161 Pregnancy after heart transplantation (HT) is a concern for many female

162 t that children with myocarditis who receive heart transplantation (HT) may be at higher risk of post

163 Malignancy is a major cause of late post-heart transplantation (HT) mortality.

164 surveillance endomyocardial biopsy (EMB) in heart transplantation (HT) patients.

165 Maintenance steroid (MS) use in pediatric heart transplantation (HT) varies across centers.

166 tudy was to assess the survival benefit from heart transplantation (HT), defined as reduction in the

167 ) have been questioned in the current era of heart transplantation (HT), where the advances in immuno

168 ) remains a leading cause of mortality after heart transplantation (HT).

169 (SRL) as primary immunosuppression following heart transplantation (HT).

170 erapy for heart failure in patients awaiting heart transplantation (HT).

171 We assessed HRR after pediatric heart transplantation (HTx) and its prognostic use.

172 lood pressure monitoring up to 3 years after heart transplantation (HTx) in 83 patients.

173 Albuminuria in maintenance heart transplantation (HTx) is associated with poor rena

174 ulatory devices and pharmacologic therapies, heart transplantation (HTx) is the definitive and most e

175 Young adult heart transplantation (HTx) recipients experience high m

176 of our study is to evaluate this relation in heart transplantation (HTx) recipients treated according

177 From 2005 to 2010, 77 consecutive heart transplantation (HTx) recipients were included.

178 Heart transplantation (HTx) remains the most effective l

179 Pediatric data on the impact of pre-heart transplantation (HTx) risk factors on early post-H

180 es of liver dysfunction, as a tool to assess heart transplantation (HTx) urgency in ambulatory patien

181 Among the various complications of heart transplantation (HTx), the vasculopathy of the all

182 pite of this, there is hesitancy to consider heart transplantation (HTx).

183 n important aspect for patient outcome after heart transplantation (HTX).

184 Lactic acidosis (LA) frequently occurs after heart transplantation (HTx).

185 erated fibrotic remodeling in children after heart transplantation (HTx).

186 limitation in long-term graft survival after heart transplantation (HTx).

187 IFI) is associated with high mortality after heart transplantation (HTx).

188 mance remains limited in some patients after heart transplantation (HTx).

189 intensity exercise should be performed after heart transplantation (HTx).

190 were collected from pediatric patients after heart transplantation (HTx, n=57), renal transplantation

191 Thrombosis was managed by heart transplantation in 11 patients (1 patient died 31

192 e exchange to an implantable VAD in 15%, and heart transplantation in 18%.

193 stcardiotomy shock in 37, graft failure post-heart transplantation in 22, and right ventricular failu

194 lation was the bridge to LVAD in 6.9% and to heart transplantation in 3.5% of patients.

195 The association of SED with survival after heart transplantation in England, where there is univers

196 Heart transplantation in patients supported by venoarter

197 d tool for donor-recipient size matching for heart transplantation in the United Kingdom.

198 ese data indicate that implementation of DCD heart transplantation in the United States would improve

199 tation (BTT)-VAD approach relative to direct heart transplantation in transplant-eligible patients.

200 The authors studied heart transplantations in CHD patients age >=18 years us

201 may reduce rates of CMV-related events after heart transplantation, including the incidence of acute

202 Health insurance status at heart transplantation influences recipient survival, but

203 ansplant acute kidney injury after liver and heart transplantation, integrating discussion of protein

204 es following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative recipients with

205 Heart transplantation is a life-saving procedure that ha

206 Heart transplantation is an established treatment for ad

207 Heart transplantation is an established, valuable therap

208 ition from private to public insurance after heart transplantation is associated with worse long-term

209 Nonetheless, the potential of DCD heart transplantation is being reconsidered, after repor

210 The field of heart transplantation is continually adapting to the gro

211 Donation after circulatory death (DCD) heart transplantation is currently being performed in th

212 ital heart disease (CHD) patients undergoing heart transplantation is increasing rapidly.

213 Heart transplantation is the most effective therapy for

214 ne of the most promising new alternatives to heart transplantation is use of ventricular assist devic

215 In advanced HF, the criteria for heart transplantation, left ventricular assist device, a

216 Potential heart transplantation/left ventricular assist device can

217 was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard

218 Instead, referral for heart transplantation may offer their best chance at lon

219 function and size; 51% had died or undergone heart transplantation (median, 3.2 months), and 27% had

220 attenuated graft rejection in a heterotopic heart transplantation model.

221 We used murine heart transplantation models to confirm that endothelial

222 o image CCR2+ monocytes and macrophages in a heart transplantation mouse model.

223 age 1 year or older, with a rate of death or heart transplantation of 3% (95% CI 1-5) at 2 years.

224 ypes also did poorly, with rates of death or heart transplantation of 45% (95% CI 32-58) at 2 years f

225 culatory support, and outcomes of orthotopic heart transplantation of these patients.

226 Heart transplantation offers the best short- and long-te

227 tion policy change on outcomes of orthotopic heart transplantation (OHT) in patients bridged with int

228 entricular (LV) dysfunction after orthotopic heart transplantation (OHT) is multifactorial and can be

229 Although orthotopic heart transplantation (OHT) remains the preferred treatm

230 otrope-dependent medical therapy, orthotopic heart transplantation (OHT), left ventricular assist dev

231 of morbidity and mortality after orthotopic heart transplantation (OHT).

232 of a specific protocol, patients bridged to heart transplantation on extracorporeal membrane oxygena

233 nt with symptomatic cardiomyopathy undergo a heart transplantation or die within the first 2 years af

234 within 2 years of diagnosis later underwent heart transplantation or died.

235 heart failure (ie, requiring medications or heart transplantation or leading to death).

236 vanced heart failure patients at the time of heart transplantation or left ventricular assist device

237 Eight men and 8 women (28%) underwent heart transplantation or received an LV assist device.

238 nts with severe heart failure as a bridge to heart transplantation or recovery.

239 onary artery dissections, and 5 women needed heart transplantation or ventricular assist device impla

240 tive for patients who are not candidates for heart transplantation or who are waiting for a suitable

241 -0.97]), living alone (OR=2.78 [1.09-7.09]), heart transplantation (OR=3.49 [1.34-9.09]), and being o

242 Patients were followed to device explant, heart transplantation, or death.

243 e mortality; 2) heart failure-related death, heart transplantation, or destination left ventricular a

244 omposite of all-cause mortality, listing for heart transplantation, or initiation of palliative care.

245 te primary end point of all-cause mortality, heart transplantation, or left ventricular assist device

246 lantable cardioverter-defibrillators (ICDs), heart transplantation, or other therapeutic measures hav

247 om death, left ventricular assist device, or heart transplantation over 4 years.

248 s over 18 years old with a first noncombined heart transplantation performed between 2012 and 2016 we

249 or those not considered to be candidates for heart transplantation, previously referred to as destina

250 Heart transplantation recipients aged 2 to 40 years, tra

251 e review that includes 279 consecutive adult heart transplantation recipients from January 2008 to Se

252 In heart transplantation, registry analyses have shown that

253 which initiate inflammatory responses after heart transplantation remain elusive.

254 Heart transplantations remain rare owing to frequent inv

255 Heart transplantation remains the preferred option for i

256 ients, however, have been excluded from most heart transplantation research.

257 recipients 2 weeks before heterotopic DBA/2J heart transplantation resulted in prolonged allograft su

258 with heart failure or those with orthotopic heart transplantation, serum levels and endothelial expr

259 m subjects with Chagas disease who underwent heart transplantation showed the expression of Gal-3 in

260 death/ventricular assist device implantation/heart transplantation (standardized hazard ratio, 0.62 [

261 nt with specific cell ablation and embryonic heart transplantation studies, we identified a unique se

262 he primary end point of all-cause mortality, heart transplantation, sudden cardiac death, and appropr

263 Heart transplantation survival is comparable to that of

264 defined as the occurrence of cardiac death, heart transplantation, survived sudden cardiac death, ve

265 isease are more likely to die while awaiting heart transplantation than men, white patients, and thos

266 sequencing and prioritizing advanced HF and heart transplantation therapeutic options in patients wi

267 ably less evidence is available in pediatric heart transplantation, though similar indications in the

268 re adoptively transferred before heterotopic heart transplantation to assess allograft survival.

269 a summary of the experimental studies on rat heart transplantation to illustrate changes that occur t

270 Mean time from heart transplantation to NMB reversal was 2.9 +/- 3.2 (m

271 preclinical studies in animal models of DCD heart transplantation, to facilitate and promote the mos

272 Heart transplantation using donor hearts adequately pres

273 urrence on the composite outcome of death or heart transplantation using VT recurrence as a time-vary

274 associated liver disease or when to consider heart transplantation versus combined heart-liver transp

275 ing enrolment, the recipient's status on the heart transplantation waiting list was updated to reflec

276 ile range, 5-15 d) and median follow-up post heart transplantation was 20.7 months.

277 on (n=187), the rate of in-hospital death or heart transplantation was 25.5% versus 0% in FM versus N

278 urring immediately post ablation on death or heart transplantation was 3.45 (2.33-5.11) in reference

279 ism, for whom the estimated rate of death or heart transplantation was 57% (95% CI 44-69) at 2 years.

280 The median time from recurrence to death or heart transplantation was 65 and 198.5 days in patients

281 n extracorporeal membrane oxygenation before heart transplantation was 9 days (interquartile range, 5

282 mortality, LV assist device implantation, or heart transplantation was assessed.

283 Decreased graft loss in pediatric heart transplantation was associated with a higher degre

284 Net benefit from heart transplantation was evident across all estimates o

285 trophic cardiomyopathy, the risk of death or heart transplantation was greatest for those who present

286 on in viral, fungal, and Nocardia IEps after heart transplantation was observed, most likely due to a

287 Heart transplantation was performed in 12 patients with

288 rdiomyopathy subgroups, the risk of death or heart transplantation was significantly increased when t

289 Using a mouse model of MHC-mismatched heart transplantation, we report markedly protective eff

290 Specific aspects relevant for DCD heart transplantation were analyzed, including animal mo

291 Factors associated with death or heart transplantation were determined for each interval.

292 echocardiograms; patients with simultaneous heart transplantation were excluded.

293 Orthotopic kidney and heterotopic heart transplantation were performed in different Lewis

294 /-15 years; 29% women; 5.0+/-5.4 years after heart transplantation) were included.

295 ars to be associated with factors other than heart transplantation, which was equally prevalent in bo

296 he explanted hearts of 6 patients undergoing heart transplantation who had prospectively undergone CM

297 center for patients with a history of prior heart transplantation who underwent anesthesia including

298 25 patients underwent heart transplantation with HCV-positive donor hearts (20

299 Heart transplantation with or without mechanical circula

300 iomyopathy is the most common indication for heart transplantation worldwide, and coxsackie B viruses